Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Cancer Collaboration Brings an 8-Million-Dollar Award to 3 Teams, Including Semir Beyaz's

Cancer Collaboration Brings an 8-Million-Dollar Award to 3 Teams, Including Semir Beyaz's

The Mark Foundation for Cancer Research announced the inaugural recipients of its Endeavor Awards and that online applications for new Endeavor Awards are now open.

The first Endeavor projects focus specifically on 3 difficult problems in cancer research:

  • metastasis —preventing and overcoming it,
  • decoding the whole-body response to cancer, and
  • understanding the molecular mechanisms of tumor plasticity and progression.

The Mark Foundation Endeavor Awards were created to bring together scientists with diverse expertise to address urgent questions in cancer research. This collaborative program enables teams of researchers working at a single institution or across multiple organizations to tackle cancer research challenges too complex for a single laboratory to address on its own.

Collaboration Is the Key to Success in Science!

Michele Cleary, CEO of The Mark Foundation, says, "Collaboration is the key to success in science," adding, "Our funding brings together researchers who are passionate about solving a shared problem and have highly complementary skills and expertise that, when applied together, accelerate the discovery of new knowledge and solutions."

The following 3 teams won the first Endeavor Awards:

  • A team at the University of California, San Francisco (UCSF);
  • A team from Cold Spring Harbor Laboratory (CSHL) led by Semir Beyaz; and
  • A multicenter research team from Columbia University, Memorial Sloan Kettering Cancer Center, and Johns Hopkins University School of Medicine.

Understanding and Eliminating Metastatic Cancers

The UCSF team aims to understand the rulebook of metastatic cancer more fully and develop therapies to prevent or eliminate it, bringing together 6 scientists with expertise across a wide range of disciplines.

Metastasis is the greatest challenge faced by people with cancer. In fact, approximately 90% of cancer deaths can be attributed to metastatic disease rather than a patient's primary tumor. Metastasis occurs when individual cancer cells spread to other tissues and survive to form secondary tumors that are often more resistant to treatment than the original tumor.

A New Approach to Metastasis

Until now, our understanding of metastasis has been limited by difficulties in determining where, when, and how tumor cells interact with other tissues as they spread. Through this project, researchers aim to get to the roots of metastasis by studying subsets of different tumor cells, including cancer stem cells, using single-cell analysis and a "multi-omic" approach (including genomics, epigenomics, transcriptomics, and proteomics).

Jeroen Roose, professor and vice chair in the UCSF Department of Anatomy and cofounder of the UCSF Bakar ImmunoX Initiative, said, “Metastasis is like a perfect storm.” He added, “We know that cancer cells form tumors all the time, but they rarely metastasize. If we understood the rules of metastasis, we could monitor a patient's cancer much better and predict when or how their particular tumors would metastasize. It would be an incredible advance."

This project aims to increase understanding of tumor heterogeneity in the metastatic setting, which will help unravel how particular tumor cells acquire the ability to spread and thrive in new environments. It also focuses on understanding the role of tumor-host interactions in metastasis, including elements of the tumor microenvironment that encourage metastatic cells to emerge, the role of the immune system, and how tumor-nerve interactions in the extracellular matrix are related. Researchers are also using organoid and animal models to identify the weak spots / vulnerabilities of metastatic tumor cells and ultimately apply these findings to develop new treatment strategies.

Decoding the Host Response to Cancer

With the participation of internationally renowned molecular biology and genetics specialist Semir Beyaz, the Cold Spring Harbor Laboratory (CSHL) team focuses on decoding the complex whole-body response to cancer. The aim of this research is to reveal systemic biological changes that may occur in the body after cancer develops.

Researchers want to gain a deeper understanding of interactions between cancer cells and other tissues in the body to connect the behavioral, neuroendocrine, metabolic, microbiome, and integrated immune responses that arise during cancer progression. They will start with mouse models and then apply what they learn to human cancer.

Bruce Stillman, president and CEO of Cold Spring Harbor Laboratory, said, “Cold Spring Harbor Laboratory has launched a major new program in whole-body physiology focused on understanding brain-body interactions.” He added, “An important component of the initiative is understanding how cancer affects our physiology, and I am delighted to collaborate with The Mark Foundation with the support of Tobias Janowitz and Semir Beyaz. These researchers have very exciting research programs that will be greatly enhanced by support from The Mark Foundation."

The Systemic Effects of Cancers

Although cancers have traditionally been classified by their tissue of origin, cancer is a systemic disease that can affect many parts of the body. This is particularly true of epithelial cancers such as colorectal, lung, pancreatic, and kidney cancers. An example of cancer's systemic effects is a wasting syndrome common in patients with advanced disease, cachexia. Cancer can also have a far-reaching impact on other aspects of the human experience, such as sleep and metabolism.

The first part of this effort aims to examine cancer's wide-ranging, systemic effects, including its interactions with the host's neuroendocrine system, immune system, and microbiome. Researchers are using experimental animal models and patient samples in their studies. They expect this approach to be synergistic, using the same samples to examine a range of different connections so that data obtained can be integrated more easily across experiments.

Data collected from this project may be used to develop organ-system-specific cancer models, which can then be used to build potential host-response models. These models have implications for predicting disease outcomes and treatment response in patients.

The CSHL team is led by Donaldson Translational Fellow and Cancer Center Member Semir Beyaz and Cancer Center Member Tobias Janowitz.

Molecular Mechanisms of Tumor Progression and Plasticity

Researchers from three major cancer centers on the East Coast came together to study plasticity (flexibility) with a focus on how it drives bladder cancer progression and how cancer cells change their fates.

Bladder cancer can occur in two forms. The more common non-muscle-invasive (not spread) bladder cancer has a better prognosis (disease course), whereas the less common muscle-invasive bladder cancer is associated with poor clinical outcomes. These two types of bladder cancer were once considered different diseases, but recent studies using advances in genetic analysis and genetically engineered mouse models show how bladder cancer can progress from non-muscle-invasive to invasive.

"Lineage" plasticity, a cell's ability to switch from one fate to another, appears to play a central role in this progression. Team members showed that epigenetic reprogramming may serve as a critical mediator of tumor-cell lineage plasticity. In recent years, important progress has been made in targeting epigenetic regulators for cancer treatment, offering hope that these studies may ultimately lead to new treatment options for patients with bladder cancer.

Through this project, researchers aim to better understand the molecular mechanisms regulating lineage plasticity in bladder cancer by integrating their expertise in clinical and translational (between basic and clinical) medicine. A defining component of their research is an ambitious and comprehensive plan to apply the latest histopathological, genomic, and computational methods to characterize a unique set of bladder cancer specimens from patients whose cancer has progressed from non-muscle-invasive to invasive.

Researchers anticipate that findings from their studies will lead to better methods of identifying patients at high risk of progressive disease, thereby enabling new clinical trials and improving clinical outcomes by offering better treatment options to patients with early-stage bladder cancer.

About The Mark Foundation Endeavor Awards

In selecting teams to receive the first Endeavor Awards, The Mark Foundation leadership sought multidisciplinary, collaborative projects that brought researchers together to begin exploring important questions in cancer research. These projects address problems with the potential to ultimately bring important improvements to the lives of people with cancer.

One aim of the Endeavor Award program is to seed research projects that may ultimately lead to larger projects that could be funded by The Mark Foundation.

Cleary says, "In selecting these first recipients, we looked for projects that would not be funded by other sources." She adds, “With this program, we are ready to take more risks and work with scientists who have great ideas. And we want to make sure that the scientists we fund have all the resources they need to move forward and do it faster."

The Online Letters of Intent Portal for the next Endeavor Awards has opened. Letters of intent are due on 1 March. For more information, visit www.themarkfoundation.org/endeavor.

Sources

Inaugural Endeavor Award Recipients Announced. January 6, 2021. https://themarkfoundation.org/2021/01/endeavor-release/

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Cancer Collaboration Brings an 8-Million-Dollar Award to 3 Teams, Including Semir Beyaz's

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy